Viridian Therapeutics Inc. Unveils Strategic Overview Highlighting Progress in Thyroid Eye Disease and Autoimmune Portfolios

Reuters

2025/06/07

Viridian <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Unveils Strategic Overview Highlighting Progress in Thyroid Eye Disease and Autoimmune Portfolios

Viridian Therapeutics Inc. has released a corporate presentation detailing its current initiatives and advancements in therapeutic development. The company is focusing on identifying market opportunities with unmet needs and advancing next-generation strategies. Key developments include the Thyroid Eye Disease (anti-IGF-1R) portfolio, featuring Veligrotug, which has reported positive topline data and is planning a Biologics License Application in the second half of 2025. Pivotal trials are ongoing for VRDN-003, with potential subcutaneous delivery. The FcRn-Targeting Autoimmune Portfolio, including VRDN-006 and VRDN-008, is progressing with Phase 1 trials and an expected IND submission by year-end 2025. Financially, Viridian reports $637 million in cash as of March 31, 2025, with a runway into the second half of 2027. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viridian Therapeutics Inc. published the original content used to generate this news brief on June 06, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2541867289"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2541867289\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2541867289?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-07 02:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2541867289","market":"nz","top_or_hot":-1,"title":"Viridian Therapeutics Inc. Unveils Strategic Overview Highlighting Progress in Thyroid Eye Disease and Autoimmune Portfolios","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Viridian <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Unveils Strategic Overview Highlighting Progress in Thyroid Eye Disease and Autoimmune Portfolios\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Viridian Therapeutics Inc. has released a corporate presentation detailing its current initiatives and advancements in therapeutic development. The company is focusing on identifying market opportunities with unmet needs and advancing next-generation strategies. Key developments include the Thyroid Eye Disease (anti-IGF-1R) portfolio, featuring Veligrotug, which has reported positive topline data and is planning a Biologics License Application in the second half of 2025. Pivotal trials are ongoing for VRDN-003, with potential subcutaneous delivery. The FcRn-Targeting Autoimmune Portfolio, including VRDN-006 and VRDN-008, is progressing with Phase 1 trials and an expected IND submission by year-end 2025. Financially, Viridian reports $637 million in cash as of March 31, 2025, with a runway into the second half of 2027. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viridian Therapeutics Inc. published the original content used to generate this news brief on June 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viridian Therapeutics Inc. Unveils Strategic Overview Highlighting Progress in Thyroid Eye Disease and Autoimmune Portfolios</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViridian Therapeutics Inc. Unveils Strategic Overview Highlighting Progress in Thyroid Eye Disease and Autoimmune Portfolios\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-07 02:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Viridian <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Unveils Strategic Overview Highlighting Progress in Thyroid Eye Disease and Autoimmune Portfolios\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Viridian Therapeutics Inc. has released a corporate presentation detailing its current initiatives and advancements in therapeutic development. The company is focusing on identifying market opportunities with unmet needs and advancing next-generation strategies. Key developments include the Thyroid Eye Disease (anti-IGF-1R) portfolio, featuring Veligrotug, which has reported positive topline data and is planning a Biologics License Application in the second half of 2025. Pivotal trials are ongoing for VRDN-003, with potential subcutaneous delivery. The FcRn-Targeting Autoimmune Portfolio, including VRDN-006 and VRDN-008, is progressing with Phase 1 trials and an expected IND submission by year-end 2025. Financially, Viridian reports $637 million in cash as of March 31, 2025, with a runway into the second half of 2027. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viridian Therapeutics Inc. published the original content used to generate this news brief on June 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDLWw23J:1","article_id":"2541867289","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2541867289","pubTimestamp":1749235242,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Viridian Therapeutics Inc. has released a corporate presentation detailing its current initiatives and advancements in therapeutic development. The company is focusing on identifying market opportunities with unmet needs and advancing next-generation strategies. Key developments include the Thyroid Eye Disease  portfolio, featuring Veligrotug, which has reported positive topline data and is planning a Biologics License Application in the second half of 2025. Pivotal trials are ongoing for VRDN-003, with potential subcutaneous delivery. The FcRn-Targeting Autoimmune Portfolio, including VRDN-006 and VRDN-008, is progressing with Phase 1 trials and an expected IND submission by year-end 2025. Financially, Viridian reports $637 million in cash as of March 31, 2025, with a runway into the second half of 2027. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strive","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VRDN":"Viridian Therapeutics, Inc."},"translate_title":"Viridian Therapeutics Inc.公布战略概述，强调甲状腺眼病和自身免疫性疾病产品组合的进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRDN":0.9},"content_text":"Viridian Therapeutics Inc. Unveils Strategic Overview Highlighting Progress in Thyroid Eye Disease and Autoimmune Portfolios\n    \n\n        Viridian Therapeutics Inc. has released a corporate presentation detailing its current initiatives and advancements in therapeutic development. The company is focusing on identifying market opportunities with unmet needs and advancing next-generation strategies. Key developments include the Thyroid Eye Disease (anti-IGF-1R) portfolio, featuring Veligrotug, which has reported positive topline data and is planning a Biologics License Application in the second half of 2025. Pivotal trials are ongoing for VRDN-003, with potential subcutaneous delivery. The FcRn-Targeting Autoimmune Portfolio, including VRDN-006 and VRDN-008, is progressing with Phase 1 trials and an expected IND submission by year-end 2025. Financially, Viridian reports $637 million in cash as of March 31, 2025, with a runway into the second half of 2027. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viridian Therapeutics Inc. published the original content used to generate this news brief on June 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}